Originally published In Press as doi:10.1074/jbc.M200740200 on April 15, 2002
J. Biol. Chem., Vol. 277, Issue 25, 22515-22519, June 21, 2002
Myb-binding Protein 1a Augments AhR-dependent Gene
Expression*
Letetia C.
Jones
,
Steven T.
Okino§,
Thomas J.
Gonda¶, and
James P.
Whitlock Jr.§
From the
Division of Hematology and Oncology, Cedars
Sinai Medical Center, UCLA School of Medicine, Los Angeles,
California 90048, the § Department of Molecular
Pharmacology, Stanford University School of Medicine, Stanford,
California 94305, and the ¶ Hanson Centre for Cancer Research,
Institute of Medical and Veterinary Science, Adelaide, South
Australia 5000
Received for publication, January 23, 2002, and in revised form, April 1, 2002
 |
ABSTRACT |
We have studied the mechanism by which an acidic
domain (amino acids 515-583) of the aromatic hydrocarbon receptor
(AhR) transactivates a target gene. Studies with glutathione
S-transferase fusion proteins demonstrate that the
wild-type acidic domain associates in vitro with
Myb-binding protein 1a, whereas a mutant domain (F542A, I569A) does
not. AhR-defective cells reconstituted with an AhR containing the
wild-type acidic domain exhibit normal AhR function; however, cells
reconstituted with an AhR containing the mutant acidic domain do not
function normally. Transient transfection of Myb-binding protein 1a
into mouse hepatoma cells is associated with augmentation of
AhR-dependent gene expression. Such augmentation does not
occur when Myb-binding protein 1a is transfected into AhR-defective cells that have been reconstituted with an AhR that lacks the acidic
domain. We infer that 1) Myb-binding protein 1a associates with AhR,
thereby enhancing transactivation, and 2) the presence of AhR's acidic
domain is both necessary and sufficient for Myb-binding protein 1a to
increase AhR-dependent gene expression.
 |
INTRODUCTION |
The aromatic hydrocarbon receptor
(AhR)1 is an intracellular
protein that mediates transcriptional responses to certain
hydrophobic ligands, the most notorious of which is the widespread
environmental contaminant
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) (1-4). The liganded AhR heterodimerizes with a second protein, known as the AhR nuclear translocator (Arnt), to form a complex that
activates transcription by binding to an enhancer in the vicinity of
the TCDD-responsive target gene (5, 6). Both AhR and Arnt are
prototypical members of the basic
helix-loop-helix/Per-Arnt-Sim class of transcription
factors, which regulate gene expression in response to a variety of
environmental and developmental signals (7-11).
Much of our understanding of AhR/Arnt-dependent
transcription stems from analyses of the TCDD-inducible
CYP1A1 gene in mouse hepatoma cells; this
experimental system benefits from the availability of AhR-defective and
Arnt-defective cells. Efficient reconstitution of such cells by
retroviral infection permits analyses of AhR and Arnt mutants in a
relatively physiological setting (12-14). Studies of
CYP1A1 gene regulation in mouse hepatoma cells reveal that exposure to TCDD leads to the binding of AhR/Arnt to an enhancer upsteam of the CYP1A1 gene. The C-terminal portion of
AhR (which contains several transactivation domains) communicates the
induction signal to the neighboring promoter, which then assumes a more accessible chromatin structure and binds general transcription factors
(12, 13). Such observations reveal that the transactivation domains of
AhR facilitate enhancer-promoter communication by a process that
involves changes in the structure of promoter chromatin and occupancy
of promoter binding sites by the transcriptional machinery.
Here, we have studied AhR-dependent transactivation in more
detail; we have focused on a relatively small (69 amino acid) domain of
AhR that is rich in acidic residues and can transactivate the
native chromosomal CYP1A1 gene (13). Our observations
indicate that this acidic activation domain (AAD) of AhR
associates with a factor previously identified as Myb-binding protein
1a (Mybbp1a) and that Mybbp1a substantially augments the ability of
AhR/Arnt to activate transcription. These findings reveal new aspects
of AhR and Mybbp1a function.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The pGudLuc6.1 vector was provided by Dr. Michael
S. Denison (University of California, Davis, CA); it contains an
AhR/Arnt-dependent enhancer and the mouse mammary tumor
virus promoter upstream of a firefly luciferase reporter gene (15). The
QuikChange Site-Directed Mutagenesis Kit and Pfu DNA
polymerase were purchased from Stratagene (La Jolla, CA). The pRL-CMV
vector and Dual-Luciferase Report Assay System were purchased
from Promega (Madison, WI). The retroviral vector pMFG was derived from
the Moloney murine leukemia virus (16). The Phoenix-eco retroviral
producer cell line (17) was provided by Dr. Garry Nolan (Stanford
University). The pGEX-2T vector and glutathione-Sepharose were
purchased from Amersham Biosciences. [
-32]dCTP
(3,000 Ci/mmol) and Renaissance Chemiluminescence Kit were purchased from PerkinElmer Life Sciences. The RNeasy Kit was
from Qiagen (Valencia, CA). Reagents for SDS-PAGE and silver staining were from Bio-Rad. Hyperfilm MP was from Amersham Biosciences. Tissue
culture reagents were from Life Invitrogen.
Cell Culture--
Wild-type (Hepa1c1c7) and AhR-defective
(Taoc1BPrcl) mouse hepatoma cells were cultured as
described previously (18). Phoenix cells were cultured as described
previously (17).
Plasmid Construction--
Mutations to alanine were made in
AhR's acidic segment at Phe542 and
Ile569 using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene) according to the manufacturer's instructions.
Plasmid pGAhR515-583 (13) was as used as a template for
the sense and antisense mutation primers. Mutations were confirmed by
nucleotide sequencing.
Wild-type and mutant pGAhR515-583 plasmids were used as
templates to PCR amplify sequences encoding AhR amino acids 515-583
for insertion into pMFGAhR494 (13). Both the forward primer
(5'-ACTACTGCAGCGGCCGCACTCTCTGGCGGCCCCTCAGAG-3') and reverse primer
(5'-ACTACTGCAGCGGCCGCTCACAGGGAATCCTGCACGTAGGT-3') contained NotI sites (underlined), and the reverse primer
contained a stop codon (bold). The PCR products were digested with
NotI and subcloned into the internal NotI site
(amino acids 492-494) of AhR in plasmid pMFGAhR494.
Wild-type and mutant pGAhR515-593 (13) were also amplified
for insertion into pGEX-2T, an expression plasmid for glutathione S-transferase fusion proteins. A linker sequence containing
a BamHI site was attached to the forward primer, and the
reverse primer was linked to an EcoRI site. The resulting
PCR products were ligated in-frame into BamHI and
EcoRI sites within the polylinker region of pGEX-2T,
generating plasmids pGST-AAD and pGST-mutAAD.
Construction of the expression plasmid for Mybbp1a has been described
previously (19).
Expression of GST Fusion Proteins and GST Pull-down
Assays--
GST fusion proteins were expressed in Escherichia
coli by induction with 0.5 mM isopropyl
-D-thiogalactopyranoside. Cells were lysed 3 h
after induction by five successive freeze-thaw cycles. After
centrifugation, the lysates were incubated with GST-Sepharose beads
(500 µl per 500-ml culture) for 30 min at room temperature. The beads
were gently pelleted and then washed extensively with
phosphate-buffered saline.
Whole-cell extracts were prepared from mouse hepatoma cells as
described previously (20) and were incubated with GST fusion proteins
(~10 µg) in NETN buffer (20 mM Tris (pH 8), 150 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) for
1 h at 4 °C with shaking. After the binding reaction, the beads
were washed five times with binding buffer and then boiled in SDS
sample buffer. The solubilized proteins were fractionated on SDS gels
and visualized by silver staining. For protein sequencing, binding
reactions were scaled up 10-fold, fractionated by SDS-PAGE, and
transferred to Immobilon-PSQ for protein microsequencing.
Protein sequence determination was performed by the Protein/DNA
Technology Center of the Rockefeller University (21, 22).
Transient Transfections--
Wild-type or reconstituted
AhR-defective mouse hepatoma cells were plated in 35-mm six-well tissue
culture dishes and incubated overnight. Cells were co-transfected using
a polybrene method (23) with 2 µg of pGudLuc6.1, 10 ng of pRL-Luc
(expression plasmid for Renilla luciferase, used to control
for transfection efficiency) (Promega), and 0, 0.5, 1.0, 2.5, or 5.0 µg of Mybbp1a expression plasmid. Twenty-four hours after
transfection, luciferase activities were determined using the
Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer's instructions. Light production was measured using a
Lumat LB 9507 luminometer. All experiments were performed at least
three times, and the data are expressed as mean ± S.E.
Retroviral Expression of AhR--
Five micrograms of pMFGAhR,
pMFGAhR494, pMFGAhR494/515-583, and the
pMFGAhR494-515-583 mutants were transfected into the
ectotropic packaging cell line, Phoenix, as described previously (17).
Recovery of retroviruses and infection of AhR-defective mouse hepatoma
cells was carried out as described previously (12).
Analysis of CYP1A1 Gene Expression--
Wild-type,
AhR-defective, and reconstituted mouse hepatoma cells were grown to
~80% confluence in 100-mm tissue culture dishes and were treated
with 1 nM TCDD or 0.1% Me2SO for
18 h. Total RNA was isolated using RNeasy spin columns (Qiagen).
Total RNA (5 µg) was fractionated on 1.2% agarose-2.2 M
formaldehyde gels, transferred to Nytran by capillary blotting in
20 × SSC, and cross-linked to the membrane in a UV Stratalinker
2400 (Stratagene). Blots were hybridized with 32P-labeled
CYP1A1 or actin cDNA overnight at 55 °C using ExpressHyb hybridization solution (CLONTECH). Blots
were washed as described previously (24) and then autoradiographed with
Hyperfilm MP (Amersham Biosciences).
Immunoblotting Analysis--
Whole-cell extracts were prepared
from wild-type, AhR-defective, and reconstituted cells as described
above. Forty micrograms of cellular proteins were dissolved in 2×
Laemmli sample buffer (Bio-Rad), fractionated by SDS-PAGE, and
transferred to a polyvinylidene difluoride membrane. Blots were
incubated in blocking buffer (20 mM Tris (pH 7.6), 137 mM NaCl, 0.1% Tween 20 (TBS-T) containing 5% nonfat milk)
overnight at 4 °C. Incubation with primary antibody (anti-AhR,
1:2000) (25) was carried out for 1 h at room temperature. After
several washes in blocking buffer, blots were incubated with secondary
antibody (anti-mouse-HRP, 1:2000) for 1 h at room temperature.
After washing in TBS-T, blots were developed using the Renaissance
Chemiluminescence Kit (PerkinElmer Life Sciences) and visualized
on Hyperfilm MP.
 |
RESULTS |
Identification of a Protein That Interacts with AhR's AAD--
We envision that transactivation by AhR involves protein-protein
interactions that facilitate communication between AhR/Arnt heterodimers bound at an enhancer and other transcription factors that
interact with the cognate promoter. To analyze the mechanism of
transactivation in further detail, we used a GST pull-down technique to
identify proteins that bind to the wild-type AAD but not to a mutant
AAD that fails to transactivate. For the mutant AAD, we targeted two
hydrophobic residues in regions previously shown to be important for
AAD function (14). The mutant contains alanine substititions at
Phe542 and Ile569 but is otherwise identical to
the wild-type AAD (aa 515-583). We fused the wild-type or mutant AAD
to AhR's N-terminal half (aa 1-494) to generate
AhR1-494/AAD and AhR1-494/mutAAD, respectively (Fig. 1A).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 1.
Structure and function of AhR
constructs. A, structural representation of AhR
constructs. B, function of AhR constructs. AhR-defective
mouse hepatoma cells were reconstituted by retroviral infection with
the indicated AhR constructs, and the response of the
CYP1A1 gene to TCDD (1 nM, 24 h)
was measured by Northern blotting.
|
|
To assess the function of the wild-type and mutant constructs, we
introduced them into AhR-defective cells by retroviral infection and
used Northern blotting to measure the response of the native chromosomal CYP1A1 target gene to TCDD. Positive and
negative control experiments reveal that reconstitution of
AhR-defective cells with full-length AhR restores responsiveness of the
CYP1A1 gene to TCDD, whereas reconstitution with
AhR1-494 does not (Fig. 1B). Reconstitution of
AhR-defective cells with the AhR1-494/AAD construct
restores TCDD-responsiveness to approximately wild-type levels; in
contrast, cells reconstituted with AhR1-494/mutAAD fail to
respond to TCDD (Fig. 1B). Immunoblotting experiments indicate that both the wild-type and mutant constructs are expressed at
nearly identical levels in the reconstituted cells. Therefore, the
failure of the mutant to transactivate is not due to underexpression of
the mutant protein (data not shown). These findings extend our previous
mutational analysis of AhR's AAD (14) by identifying a double point
mutation that abolishes function and provides a useful negative control
for GST pull-down experiments.
We constructed GST fusion proteins containing either the wild-type or
mutated AAD, attached the fusion proteins to glutathione-Sepharose beads, and allowed the beads to interact with extracts prepared from
mouse hepatoma cells. Interacting proteins were purified and analyzed
by SDS-PAGE and silver staining. Our findings reveal three proteins,
with molecular masses of about 160, 180, and 200 kDa, that interact
with the GST-AAD fusion protein but not with the GST-mutAAD fusion
protein (Fig. 2A). We isolated
enough of the most prominent (~160 kDa) AAD-interacting protein to
permit its microsequencing; the data revealed that the sequences of two tryptic peptides were identical to sequences within Mybbp1a, a nuclear
protein that interacts with c-Myb (19).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Identification of Myb-binding protein 1a as a
protein that associates with the AAD of AhR. A, GST
pull-down experiments. The indicated GST-AhR fusion proteins were used
to isolate interacting proteins, which were fractionated by SDS-PAGE
and identified by silver staining. B, immunoblotting.
Proteins interacting with the indicated GST-AhR fusion proteins were
fractionated by SDS-PAGE, transferred to a polyvinylidene difluoride
membrane, and identified by immunoblotting, using anti-Mybbp1a as the
primary antibody.
|
|
We confirmed the identity of the AAD-interacting protein in
immunoblotting experiments using an anti-Mybbp1a antibody. Our findings
indicate the presence of an immunoreactive ~160-kDa band in pull-down
eluates from GST-AAD, but not in eluates from GST-mutAAD or GST alone
(Fig. 2B). In addition, the immunoreactive band co-localized with the 160 kDa silver-stained band in a gel run in parallel (data not
shown). Together, these findings imply that Mybbp1a interacts with the
wild-type AAD but not with the mutant AAD. It is notable that the
inability of Mybbp1a to interact with the mutant AAD is associated with
loss of transactivation capability in the mutant (Fig. 1). This
observation tends to implicate Mybbp1a in the transactivation function
of the AAD.
Effect of Mybbp1a on AhR-mediated Gene Expression--
The above
findings led us to ask whether Mybbp1a affects the transactivation
capability of AhR's AAD. To address this issue, we co-transfected
mouse hepatoma cells with increasing amounts of a Mybbp1a expression
vector together with a dioxin-responsive AhR/Arnt-dependent
firefly luciferase reporter construct (pGudLuc) and measured
TCDD-inducible luciferase activity in the transfected cells. Our
findings (Fig. 3) reveal that
transfections with increased amounts of Mybbp1a expression vector are
associated with increased responsiveness of the reporter gene to TCDD.
For example, in cells that contain no Mybbp1a expression vector, TCDD
induces luciferase activity about 11-fold; in contrast, at the highest
level of Mybbp1a expression vector used, TCDD induces luciferase
activity about 56-fold. Thus, in this experimental setting, Mybbp1a can
increase the responsiveness of an AhR-dependent gene by (at
least) a factor of five.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Increasing Mybbp1a expression augments
AhR/Arnt function. Mouse hepatoma cells were co-transfected with
an AhR/Arnt-dependent firefly luciferase reporter gene, an
expression plasmid for Renilla luciferase (to control for
transfection efficiency), and the indicated amounts of a Mybbp1a
expression vector. Luciferase activity was measured in uninduced and
TCDD-induced (1 nM, 24 h) cells, and firefly
luciferase activity was normalized to Renilla luciferase
activity.
|
|
The results of the expression studies (Fig. 3), together with those of
the pull-down experiments (Fig. 2), imply that Mybbp1a influences gene
expression via AhR's AAD. To test this idea directly, we used
retroviral vectors to reconstitute AhR-defective cells with either
AhR1-494/AAD, full-length AhR (as a positive control), or
AhR1-494 (as a negative control), and we established clonal strains of each reconstituted cell type. Immunoblotting studies
confirmed that expression of the AhR constructs in each of the
reconstituted cell strains is similar to that of AhR in wild-type cells
(data not shown). We then transiently transfected these strains with
the AhR/Arnt-dependent firefly luciferase reporter construct (pGudLuc), to document that the augmentation of
AhR-dependent gene expression by Mybbp1a requires the AAD.
The positive and negative controls reveal, as expected, that Mybbp1a
augments the response of the reporter gene in cells reconstituted with
full-length AhR but not in cells reconstituted with
AhR1-494. Notably, in cells reconstituted with
AhR1-494/AAD, Mybbp1a augments luciferase expression as
effectively as it does in the positive control cells (Fig.
4). These findings imply that the AAD is
both necessary and sufficient for Mybbp1a to augment
AhR-dependent gene expression.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 4.
Augmentation of AhR/Arnt function by Mybbp1a
requires the AAD of AhR. AhR-defective cells were reconstituted by
retroviral infection with the indicated AhR constructs, and clonal
strains were established. Each strain was co-transfected with an
AhR/Arnt-dependent luciferase reporter gene either with or
without a Mybbp1a expression vector, as indicated. Luciferase activity
was measured in TCDD-induced (1 nM, 24 h) cells,
normalized to protein concentration in each of the sublines, and
expressed as specific activity. LU, light units.
|
|
 |
DISCUSSION |
To better understand the mechanism by which AhR transactivates its
target genes, we identified Mybbp1a as a factor that associates with
AhR's AAD in vitro and augments AhR function in
vivo. Our findings are consistent with previous observations that
Mybbp1a may influence transactivation in other systems (19). Prior
analyses of CYP1A1 gene regulation indicate that the
C-terminal portion of AhR mediates enhancer-promoter communication,
producing an accessible chromatin structure that facilitates promoter
occupancy (12, 13). The findings in this paper imply that Mybbp1a
participates in this process.
We have shown previously that hydrophobic residues that are clustered
in two regions of AhR's acidic segment are important for
transactivation function (14). Here, we observe that mutation of
Phe542 and Ile569 within the AAD abolishes not
only its association with Mybbp1a but also its transactivation
capability. These findings imply that hydrophobic forces are
important both for the association between the two proteins and for
transactivation function. Previous studies imply that Mybbp1a binds to
c-Myb and to c-Jun via leucine zipper-like motifs (19, 28). However,
AhR's AAD does not contain a leucine zipper; therefore, its
association with Mybbp1a must involve a different type of interaction.
This conclusion is consistent with other findings which imply that
Mybbp1a influences Myb-dependent and
AhR-dependent gene regulation by different mechanisms. For example, Mybbp1a associates with a negative regulatory domain in the
Myb protein (19). In contrast, we find that Mybbp1a interacts with a
transactivation domain of AhR. Furthermore, overexpression of Mybbp1a
fails to alter Myb-dependent gene expression (19). In
contrast, we find that overexpression of Mybbp1a augments
AhR-dependent transcription. Taken together, these
observations imply that Mybbp1a can utilize several different molecular
mechanisms to influence gene expression.
Our GST pull-down experiments reveal that Mybbp1a can associate with
AhR's AAD in vitro in the absence of TCDD. Therefore, we
infer that TCDD is not required to induce a factor(s) that facilitates
the Mybbp1a-AhR interaction. The constitutive interaction observed
in vitro may not occur in intact cells, because, for the
most part, the two proteins occupy different subcellular compartments; the unliganded AhR is cytoplasmic, while Mybbp1a is found in the nucleolus and in the nucleoplasm (19). It is conceivable that AhR
interacts with Mybbp1a in the cytoplasm because Mybbp1a exhibits nuclear-cytoplasmic
shuttling.2 However, at any
one time, most of the Mybbp1a is in the nucleus. Because of such
compartmentalization, we envision that the two proteins do not have an
opportunity to associate in vivo until the AhR enters the
nucleus following exposure of cells to TCDD or another ligand.
Our studies reveal that increased expression of Mybbp1a substantially
augments the response of an AhR/Arnt-dependent reporter gene to TCDD. This observation implies that the availability of Mybbp1a
can be a limiting factor for maximal AhR/Arnt function. We envision
that the restricted availability of Mybbp1a reflects its localization
primarily in the nucleolus (19). The mechanism by which Mybbp1a
augments AhR/Arnt function remains to be determined. We hypothesize
that Mybbp1a contributes via protein-protein interactions to the
formation of productive transcriptional complexes at
AhR/Arnt-dependent promoters. This process could involve
recruitment and/or stabilization of any of numerous factors that
participate in the transcription of genes in chromatin (29-33). In
this regard, we note that Mybbp1a contains several so-called LCD
motifs, which have been implicated in protein-protein interactions
involved in inducible gene expression in other systems (20, 34-36).
Our experiments do not reveal whether Mybbp1a is essential for AhR/Arnt
function; studies in Mybbp1a-defective cells could address this issue
in the future.
Our studies re-emphasize the concept that AhR has a modular
organization and that different domains of AhR subserve different functions. Our observation that the AAD of AhR can substitute functionally for the entire C-terminal portion of AhR (which contains several transactivation domains) suggests that the C-terminal portion
exhibits redundancy with respect to its transactivation capability. One
possible advantage of such redundancy is that it might improve the
ability of AhR/Arnt to communicate with transcriptional promoters that
differ in their cognate binding proteins. In this respect, it is
notable that a second, glutamine-rich transactivation domain within
AhR's C-terminal portion probably interacts with proteins that are
different from those that interact with the AAD (37, 38). Given this
situation, we speculate that the AAD and the glutamine-rich domain of
AhR preferentially communicate with different sets of transcriptional
promoters. This may be an interesting area for future research.
 |
ACKNOWLEDGEMENT |
We thank Len Dahand for technical assistance.
 |
FOOTNOTES |
*
This work was supported by Research Grant CA 53887 from the
National Institutes of Health (to J. P. W.) and by
Postdoctoral Fellowship PF-99-127-01 CNE from the American Cancer
Society (to L. C. J.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
650-723-8233; Fax: 650-723-2253; E-mail:
jpwhit@stanford.edu.
Published, JBC Papers in Press, April 15, 2002, DOI 10.1074/jbc.M200740200
2
T. J. Gonda, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
AhR, aromatic
hydrocarbon receptor;
AAD(s), acidic activation domain(s);
Arnt, AhR
nuclear translocator;
Mybbp1a, Myb-binding protein 1a;
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin;
GST, glutathione
S-transferase.
 |
REFERENCES |
| 1.
|
Burbach, K. M.,
Poland, A.,
and Bradfield, C. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8185-8189[Abstract/Free Full Text]
|
| 2.
|
Ema, M.,
Sogawa, K.,
Watanabe, N.,
Chujoh, Y.,
Matsushita, N.,
Gotoh, O.,
Funae, Y.,
and Fujii-Kuriyama, Y.
(1992)
Biochem. Biophys. Res. Commun.
184,
246-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Okey, A. B.,
Riddick, D. S.,
and Harper, P. A.
(1994)
Trends Pharmacol. Sci.
15,
226-232[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Swanson, H. I.,
and Bradfield, C. A.
(1993)
Pharmacogenetics
3,
213-230[Medline]
[Order article via Infotrieve]
|
| 5.
|
Hankinson, O.
(1995)
Annu. Rev. Pharmacol. Toxicol.
35,
307-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Whitlock, J. P., Jr.
(1993)
Chem. Res. Toxicol.
6,
754-763[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Reisz-Porszasz, S.,
Probst, M. R.,
Fukunaga, B. N.,
and Hankinson, O.
(1994)
Mol. Cell. Biol.
14,
6075-6086[Abstract/Free Full Text]
|
| 8.
|
Whitelaw, M. L.,
Gustafsson, J. A.,
and Poellinger, L.
(1994)
Mol. Cell. Biol.
14,
8343-8355[Abstract/Free Full Text]
|
| 9.
|
Huang, Z. J.,
Edery, I.,
and Rosbash, M.
(1993)
Nature
364,
259-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Nambu, J. R.,
Lewis, J. O.,
Wharton, K. A., Jr.,
and Crews, S. T.
(1991)
Cell
67,
1157-1167[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Gu, Y. Z.,
Hogenesch, J. B.,
and Bradfield, C. A.
(2000)
Annu. Rev. Pharmacol. Toxicol.
40,
519-561[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ko, H. P.,
Okino, S. T., Ma, Q.,
and Whitlock, J. P., Jr.
(1996)
Mol. Cell. Biol.
16,
430-436[Abstract]
|
| 13.
|
Ko, H. P.,
Okino, S. T., Ma, Q.,
and Whitlock, J. P., Jr.
(1997)
Mol. Cell. Biol.
17,
3497-3507[Abstract]
|
| 14.
|
Jones, L. C.,
and Whitlock, J. P., Jr.
(2001)
J. Biol. Chem.
276,
25037-25042[Abstract/Free Full Text]
|
| 15.
|
Garrison, P. M.,
Tullis, K.,
Aarts, J. M.,
Brouwer, A.,
Giesy, J. P.,
and Denison, M. S.
(1996)
Fundam. Appl. Toxicol.
30,
194-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Dranoff, G.,
Jaffee, E.,
Lazenby, A.,
Golumbek, P.,
Levitsky, H.,
Brose, K.,
Jackson, V.,
Hamada, H.,
Pardoll, D.,
and Mulligan, R. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3539-3543[Abstract/Free Full Text]
|
| 17.
| Swift, S., Lorens, J., Achacoso, P., and Nolan, G. P. (1999)
Current Protocols in Immunology, Unit 10.28 (Suppl.
31)
|
| 18.
|
Miller, A. G.,
Israel, D.,
and Whitlock, J. P., Jr.
(1983)
J. Biol. Chem.
258,
3523-3527[Abstract/Free Full Text]
|
| 19.
|
Tavner, F. J.,
Simpson, R.,
Tashiro, S.,
Favier, D.,
Jenkins, N. A.,
Gilbert, D. J.,
Copeland, N. G.,
Macmillan, E. M.,
Lutwyche, J.,
Keough, R. A.,
Ishii, S.,
and Gonda, T. J.
(1998)
Mol. Cell. Biol.
18,
989-1002[Abstract/Free Full Text]
|
| 20.
|
Torchia, J.,
Rose, D. W.,
Inostroza, J.,
Kamei, Y.,
Westin, S.,
Glass, C. K.,
and Rosenfeld, M. G.
(1997)
Nature
387,
677-684[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Fernandez, J.,
Gharahdaghi, F.,
and Mische, S. M.
(1998)
Electrophoresis
19,
1036-1045[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Fernandez, J.,
Andrews, L.,
and Mische, S. M.
(1994)
Anal. Biochem.
218,
112-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Fisher, J. M., Wu, L.,
Denison, M. S.,
and Whitlock, J. P., Jr.
(1990)
J. Biol. Chem.
265,
9676-9681[Abstract/Free Full Text]
|
| 24.
|
Scammell, J. G.,
Sumners, C.,
Reutter, M. A.,
Valentine, D. L.,
and Jones, L. C.
(1995)
Brain Res. Mol. Brain Res.
33,
326-332[Medline]
[Order article via Infotrieve]
|
| 25.
|
Perdew, G. H.,
Abbott, B.,
and Stanker, L. H.
(1995)
Hybridoma
14,
279-283[Medline]
[Order article via Infotrieve]
|
| 26.
| Deleted in proof
|
| 27.
| Deleted in proof
|
| 28.
|
Favier, D.,
and Gonda, T. J.
(1994)
Oncogene
9,
305-311[Medline]
[Order article via Infotrieve]
|
| 29.
|
Fyodorov, D. V.,
and Kadonaga, J. T.
(2001)
Cell
106,
523-525[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Varga-Weisz, P.
(2001)
Oncogene
20,
3076-3085[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Chinenov, Y.,
and Kerppola, T. K.
(2001)
Oncogene
20,
2438-2452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Pugh, B. F.
(2000)
Gene (Amst.)
255,
1-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Struhl, K.
(1998)
Genes Dev.
12,
599-606[Free Full Text]
|
| 34.
|
Heery, D. M.,
Hoare, S.,
Hussain, S.,
Parker, M. G.,
and Sheppard, H.
(2001)
J. Biol. Chem.
276,
6695-6702[Abstract/Free Full Text]
|
| 35.
|
Ledo, F.,
Carrion, A. M.,
Link, W. A.,
Mellstrom, B.,
and Naranjo, J. R.
(2000)
Mol. Cell. Biol.
20,
9120-9126[Abstract/Free Full Text]
|
| 36.
|
Kalkhoven, E.,
Valentine, J. E.,
Heery, D. M.,
and Parker, M. G.
(1998)
EMBO J.
17,
232-243[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Hahn, S.
(1993)
Cell
72,
481-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Triezenberg, S. J.
(1995)
Curr. Opin. Genet. Dev.
5,
190-196[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Yamauchi, R. A. Keough, T. J. Gonda, and S. Ishii
Ribosomal stress induces processing of Mybbp1a and its translocation from the nucleolus to the nucleoplasm.
Genes Cells,
January 1, 2008;
13(1):
27 - 39.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Cavellan, P. Asp, P. Percipalle, and A.-K. O. Farrants
The WSTF-SNF2h Chromatin Remodeling Complex Interacts with Several Nuclear Proteins in Transcription
J. Biol. Chem.,
June 16, 2006;
281(24):
16264 - 16271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Kim and M. R. Stallcup
Role of the Coiled-coil Coactivator (CoCoA) in Aryl Hydrocarbon Receptor-mediated Transcription
J. Biol. Chem.,
November 26, 2004;
279(48):
49842 - 49848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fan, J. Rhee, J. St-Pierre, C. Handschin, P. Puigserver, J. Lin, S. Jaeger, H. Erdjument-Bromage, P. Tempst, and B. M. Spiegelman
Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1{alpha}: modulation by p38 MAPK
Genes & Dev.,
February 1, 2004;
18(3):
278 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.